Will high-tech tests revolutionize the early detection of ovarian Ca?

Contemporary Ob/Gyn

Volumn 48, Issue 6, 2003, Pages 44-56

  Fishman, David A ^a   O'Rourke, Jennifer ^b   Karnik, Nita ^b   Singh, Diljeet ^c   Cohen, Leeber ^c  

^a NOCEDP   (United States)

^b NOCEDP ^*  (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 10044262376     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jemal A, Thomas A, Murray T, et al. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Ozols RF, Rubin SC, Thomas GM, et al. Epithelial Ovarian Cancer. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:981-1058.
3. American Cancer Society. Cancer tacts and figures, 2002. Atlanta, Ga: American Cancer Society, 2002.
4. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998:62:676-689.
5. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet. 1998;66:1259-1272.
6. Stratton JF, Pharoah P, Smith SK, et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 1998;105:493-499.
7. American Medical Association. Gene testing for breast and ovarian cancer. Chicago, IL: American Medical Association, 1997.
8. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994;343:692-695.
9. Cronin KA, Weed DL, Connor RJ, et al. Case-control studies of cancer screening: theory and practice. J Natl Cancer Inst. 1998;90:498-504.
10. Bell R, Petticrew M, Sheldon T. The performance of screening tests for ovarian cancer: results of a systemic review. Br J Obstet Gynacol. 1998:105:1136-1147.
11. van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000;77:350-356.
12. Cohen LS, Escobar PF, Scharm C, et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol. 2001;82:40-48.
13. Fishman DA, Cohen LS. Is transvaginal ultrasound effective for screening asymptomatic women for the detection of early stage epithelial ovarian carcinoma? Gynecol Oncol. 2000;77:347-349.
14. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
15. Shayesteh L, Lu Y, Kuo WL, et al. P1K3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21:99-102.
16. Fei R, Shaoyang L. Combination antigene therapy targeting c-myc and c-erbB(2) in the ovarian cancer COC(1) cell line. Gynecol Oncol. 2002;85:40-44.
17. Brooks DJ, Woodward S, Thompson FH, et al. Expression of the zinc finger gene EVL-1 in ovarian and other cancers. Br J Cancer. 1996;74:1518-1525.
18. Friedlander ML. Prognostic factors in ovarian cancer. Semin Oncol. 1998;25:305-314.
19. Gray JW, Chin K, Waldman F. A molecular cytogenic view of chromosomal heterogeneity in solid tumors. In: Mihich E, Hartwell L, eds. Genomic Instability and Immortality in Cancer. New York, NY: Plenum Press; 1997:3-32.
20. Umayahara K, Cheneviex-Trench G, Daneshvar L, et al. Molecular genetic studies. In: Sharp F, Blackett T, Berek J, eds. Ovarian Cancer. Oxford, England: ISIS Medical Media; 1998:17-24.
21. Berek JS, Bast RC Jr. Ovarian cancer screening: The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76:2092-2096.
22. Evans AC Jr, Berchuck A. Tumor markers. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and Practice of Gynecologic Oncology, 2nd ed. Philadelphia, Pa: Lippincott-Raven; 1997:177-196.
23. Schwartz PE, Chambers JT, Taylor KJ. Early detection and screening for ovarian cancer. J Cell Biochem Suppl. 1995;23:233-237.
24. Rosenthal A, Jacobs I. Ovarian cancer screening. Semin Oncol. 1998;25:315-325.
25. Petricoin EF, Zoon KC, Kohn EC, et al. Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov. 2002:1:683-695.
26. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572-577.
27. Xu Y, Shen Z, Wiper DW, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA. 1998;280:719-723.
28. Baron AT, Cora EM, Lafky JM, Fishman DA, et al Soluble Epidermal Growth Factor Receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:103-113.
29. Maihle NJ, Baron AT, Barrette BA, et al. EGF/ErbB receptor family in ovarian cancer. In: Stack MS, Fishman DA, eds. Ovarian Cancer. Boston, Mass: Kiuwer Academic Publishers; 2002:247-258.
30. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-1679.
31. Mok SC, Chao J, Skates S, et al. Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology. J Natl Cancer Inst. 2001; 93:1458-1464.
32. Gillan L, Matei D, Fishman DA, et al. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V) beta(3) and alpha(V) beta(5) integrins and promotes cell motility. Cancer Res. 2002;62:5358-5364.
33. Fishman DA, Bozorgi K. The scientific basis of early detection of epithelial ovarian cancer. In: Stack MS, Fishman DA, eds. Ovarian Cancer. Boston, Mass: Kiuwer Academic Publishers; 2002:3-28.